Radiotherapy Clinical Trial
Official title:
A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Who Had Complete Remission as Assessed by PET-CT After Immune-chemotherapy
This study is a prospective, single center, phase II clinical study involving 108 patients with primary and late stage Diffuse Large B-cell Lymphoma complicated by large masses and extranodal involvement. The study aims to evaluate the efficacy of radiotherapy targeting large masses and extranodal involvement in treatment-naïve advanced DLBCL patients with large mass lesions and/or extranodal involvement after they had initially been treated with standard immunochemotherapy and received complete remission as assessed by PET-CT. After completing the standard immunochemotherapy, subjects will be randomly divided into the radiotherapy group or the non-radiotherapy group, and the curative effects will be evaluated every three months after the end of the treatment or after their leaving the group, so as to obtain the relevant data and data of the 2-year Progression Free Survival, survival of the subjects and Treatment-related side effects.
Safety analysis: The safety analysis is mainly based on descriptive statistical analysis, which lists and describes the incidence, severity, correlation, risk and outcome of adverse events (AE) in this trial. Efficacy analysis: The Kaplan-Meier method will be used to draw the overall survival curve and the progression-free survival curve, and to estimate the median survival time, median progression-free survival period and their 95% confidence intervals. Before starting the study, patients must read and sign the current version of informed consent form approved by the Ethics Committee (EC). All research steps must be carried out within the time window specified in the research schedule. The duration of safety data collection is from the patient signing the Informed Consent Form (ICF) to the end of the study, with all AEs recorded in the CRF. The severity of AE will be evaluated based on the NCI CTCAE 5.0 standard. Each patient will undergo a series of planned visits and specific data will be recorded at different time points during the scheduled visits. All examinations/tests are recommended, and the exact examination/test items to be completed during the study shall be subject to clinical practice. Investigators must be physicians who have been trained in terms of knowledge and conduct of clinical trials and work under the guidance of senior professionals; Prior to the start of the trial, the clinical ward must be inspected so as to ensure its compliance with standardized requirements and to ensure complete readiness of rescue equipment. It is recommended that professional nursing staff administer medication to the subjects and have a detailed understanding of the medication usage to ensure patient compliance; Each investigation site must strictly follow the study protocol; All participating sites should adhere to the ICH-GCP regulations and standard operating procedures (SOPs) for preservation, and all clinical trial information should be recorded, disposed of, and saved for purposes of accurate reporting, interpretation, and verification of study results; Confirm that all data records and reports are correct and complete, and save the original and essential documents related to the study. This clinical study will be conducted in accordance with the principles established by the 18th World Federation of Medical Associations (Helsinki, 1964) and all subsequent revisions. Before enrollment, it is necessary to weigh the foreseeable risks and inconveniences that study may bring to the subjects against the potential benefits for enrolled patients. Clinical trials can only be initiated and continued when the expected benefits outweigh the risks. Prior to participating in clinical trials, each subject should provide voluntary informed consent, otherwise they cannot be screened or selected. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03212742 -
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
Recruiting |
NCT06120127 -
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
|
Phase 2 | |
Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
Recruiting |
NCT02661152 -
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
|
Phase 3 | |
Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
Completed |
NCT01168479 -
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT03658343 -
T2* MRI Analysis for Sarcoma
|
N/A | |
Completed |
NCT03280719 -
Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions
|
N/A | |
Recruiting |
NCT05514327 -
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
|
N/A | |
Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
Recruiting |
NCT03370926 -
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
|
N/A | |
Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02428049 -
Radiation Pneumonitis After SBRT for NSCLC
|
||
Recruiting |
NCT04923620 -
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
|
||
Active, not recruiting |
NCT05371795 -
Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device
|
N/A | |
Recruiting |
NCT03210428 -
Quantitative MR Imaging in Locally Advanced Cervical Cancer
|